XTRA:MF6

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

MagForce AG operates in the field of nanotechnology-based cancer treatment in Germany and Poland. More Details


Snowflake Analysis

Exceptional growth potential and slightly overvalued.

Share Price & News

How has MagForce's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MF6's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-7.8%

MF6

-0.4%

DE Medical Equipment

-4.7%

DE Market


1 Year Return

-49.6%

MF6

23.9%

DE Medical Equipment

-3.8%

DE Market

Return vs Industry: MF6 underperformed the German Medical Equipment industry which returned 23.6% over the past year.

Return vs Market: MF6 underperformed the German Market which returned -3.8% over the past year.


Shareholder returns

MF6IndustryMarket
7 Day-7.8%-0.4%-4.7%
30 Day0%5.6%-2.4%
90 Day-22.7%-2.6%-4.4%
1 Year-49.6%-49.6%25.7%23.9%-0.8%-3.8%
3 Year-68.7%-68.7%178.3%171.8%-4.5%-12.9%
5 Year-55.4%-55.4%316.3%298.7%15.5%-1.0%

Price Volatility Vs. Market

How volatile is MagForce's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is MagForce undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: MF6 (€2.39) is trading below our estimate of fair value (€16.03)

Significantly Below Fair Value: MF6 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: MF6 is unprofitable, so we can't compare its PE Ratio to the DE Medical Equipment industry average.

PE vs Market: MF6 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MF6's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MF6 is overvalued based on its PB Ratio (4.5x) compared to the DE Medical Equipment industry average (4.2x).


Next Steps

Future Growth

How is MagForce forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

63.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MF6 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.2%).

Earnings vs Market: MF6 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: MF6's is expected to become profitable in the next 3 years.

Revenue vs Market: MF6's revenue (50.5% per year) is forecast to grow faster than the German market (6% per year).

High Growth Revenue: MF6's revenue (50.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: MF6's Return on Equity is forecast to be very high in 3 years time (49.2%).


Next Steps

Past Performance

How has MagForce performed over the past 5 years?

-0.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MF6 is currently unprofitable.

Growing Profit Margin: MF6 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MF6 is unprofitable, and losses have increased over the past 5 years at a rate of 0.9% per year.

Accelerating Growth: Unable to compare MF6's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MF6 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (14.8%).


Return on Equity

High ROE: MF6 has a negative Return on Equity (-59.36%), as it is currently unprofitable.


Next Steps

Financial Health

How is MagForce's financial position?


Financial Position Analysis

Short Term Liabilities: MF6's short term assets (€1.6M) do not cover its short term liabilities (€6.5M).

Long Term Liabilities: MF6's short term assets (€1.6M) do not cover its long term liabilities (€15.4M).


Debt to Equity History and Analysis

Debt Level: MF6's debt to equity ratio (113.4%) is considered high.

Reducing Debt: Insufficient data to determine if MF6's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if MF6 has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if MF6 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is MagForce current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MF6's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MF6's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MF6's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MF6's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MF6's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

8.0yrs

Average management tenure


CEO

Ben Lipps (80 yo)

7.08yrs

Tenure

Dr. Benjamin J. Lipps, also known as Ben, serves as Director and Chief Executive Officer at MagForce USA, Inc. He has been the Chairman of the Management Board and Chief Executive Officer at MagForce AG si ...


Leadership Team

NamePositionTenureCompensationOwnership
Benjamin Lipps
Chairman of the Management Board & CEO7.08yrsno datano data
Christian Von Volkmann
CFO & Member of Management Board8yrsno datano data
Hoda Tawfik
Chief Medical Officer & Member of Management Board8yrsno datano data
Andreas Jordan
Executive VPno datano datano data
Barbara Frankenberg
Vice President of Communications & Investor Relations4.58yrsno datano data
Solveig Salomon
VP of Marketing & Sales and European Commercial Directorno datano datano data
Hans Hutt
Medical Consultant9.92yrsno datano data

8.0yrs

Average Tenure

63yo

Average Age

Experienced Management: MF6's management team is seasoned and experienced (8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

MagForce AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: MagForce AG
  • Ticker: MF6
  • Exchange: XTRA
  • Founded: 1997
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: €66.215m
  • Shares outstanding: 27.71m
  • Website: https://www.magforce.com

Number of Employees


Location

  • MagForce AG
  • Max-Planck-Strasse 3
  • Berlin
  • Berlin
  • 12489
  • Germany

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MF6DB (Deutsche Boerse AG)YesCommon StockDEEURSep 2007
MF6XTRA (XETRA Trading Platform)YesCommon StockDEEURSep 2007
MGFR.FOTCPK (Pink Sheets LLC)YesCommon StockUSUSDSep 2007
0W10LSE (London Stock Exchange)YesCommon StockGBEURSep 2007

Biography

MagForce AG operates in the field of nanotechnology-based cancer treatment in Germany and Poland. It offers NanoTherm therapy for the treatment of solid tumors; NanoTherm, a ferrofluid liquid containing su ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/28 21:22
End of Day Share Price2020/10/28 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.